Amgen
AMGN BiotechPioneer biotechnology company with strength in oncology and inflammation. Known for biologics innovation including Enbrel, Repatha, and biosimilar portfolio.
FDA Novel Drug Designations
(2018-2024)See 4 novel approvals →
Amgen at a Glance
- Leading 15 drug targets across portfolio
- Fast trial execution (27 months median completion)
Amgen's Key Drugs
Amgen's core commercial portfolio centers on REPATHA, OTEZLA, EVENITY, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
Major adverse cardiovascular events in adults at increased risk
Active psoriatic arthritis
Osteoporosis
Acute Lymphoblastic Leukemia
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
Amgen's Recent FDA Approvals
Amgen secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Amgen's Therapeutic Areas
Amgen's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 11 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Amgen's Top Competitors
Amgen's closest competitors by therapeutic-area and drug-target overlap include Takeda, Johnson & Johnson, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Amgen Pipeline Snapshot
Amgen has 407 active clinical programs from ClinicalTrials.gov — 131 Phase 3, 83 Phase 2 and 193 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 148/214 completed
- • Speed: 27 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges